ストックスクリーナーアプリを入手
90.43
2.25%
1.99
アフターアワーズ：
91.50
1.07
+1.18%
Palvella Therapeutics Inc (PVLA) 最新ニュース
Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin - MSN
Earnings Recap: Will Palvella Therapeutics Inc stock pay special dividendsEarnings Recap Report & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Palvella Therapeutics (NASDAQ:PVLA) Trading Down 4.9% – What’s Next? - Defense World
Stifel Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - MSN
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 4.9%Here's What Happened - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 3.9% – Still a Buy? - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Trading Up 3.9%Should You Buy? - MarketBeat
12 Overlooked Stocks That Delivered Massive Gains In 2025 - RTTNews
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1% – Should You Buy? - Defense World
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock enhance shareholder valueSector-Based Investing & Free Proven Portfolio Growth Strategies - Bollywood Helpline
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1%Time to Buy? - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 5.9%Here's What Happened - MarketBeat
Published on: 2025-12-23 22:49:55 - bollywoodhelpline.com
FDA Fast Track Puts Palvella’s Rare Skin Drug on a Faster Regulatory Path - MyChesCo
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst (NASDAQ:PVLA) - Seeking Alpha
Rare disease breakthrough? Palvella reports strong phase 2 results - MSN
Rare Disease Breakthrough? Palvella Reports Strong Phase 2 Results - MyChesCo
Palvella Therapeutics stock hits 52-week high at 112.4 USD By Investing.com - Investing.com Australia
Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week HighStill a Buy? - MarketBeat
Palvella Therapeutics stock hits 52-week high at 112.4 USD - Investing.com
Palvella Therapeutics, Inc.(NasdaqCM:PVLA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Palvella Therapeutics (PVLA) Price Target Increased by 33.50% to 178.50 - Nasdaq
Adagene, Palvella gain after FDA fast track designations - MSN
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin - Finviz
Will Palvella Therapeutics Inc. stock gain from lower inflation2025 Earnings Impact & Fast Gain Stock Tips - Улправда
Assessing Palvella Therapeutics’ Valuation After Its Rare Disease Momentum-Driven Surge in 2024 - Yahoo Finance
Buy Signal: Can Palvella Therapeutics Inc. (PI6) stock survive global slowdownQuarterly Profit Report & AI Enhanced Execution Alerts - Улправда
Will Palvella Therapeutics Inc. stock attract ESG investorsTrade Signal Summary & Real-Time Market Sentiment Reports - Улправда
How Palvella Therapeutics Inc. stock trades before earningsJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - Улправда
Will Palvella Therapeutics Inc. stock continue upward momentumGlobal Markets & Weekly High Momentum Picks - Улправда
Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,302 Shares - MarketBeat
Palvella Therapeutics COO Kathleen Goin Sells Shares - TradingView — Track All Markets
The $100 ClubWere You Early To The Triple-Digit Rally In ABVX, NUTX, BLTE…? - RTTNews
What is the fair value of Palvella Therapeutics Inc. stock nowJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - DonanımHaber
12 Best Multibagger Stocks to Buy Heading into 2026 - Insider Monkey
Buy Signal: Is Palvella Therapeutics Inc. stock a buy for dividend growth2025 Price Momentum & AI Powered Trade Plan Recommendations - DonanımHaber
Can Palvella Therapeutics Inc. stock deliver surprise earnings beatMarket Activity Summary & Weekly High Potential Stock Alerts - ulpravda.ru
What is HC Wainwright's Forecast for PVLA FY2027 Earnings? - MarketBeat
FY2026 EPS Estimates for PVLA Decreased by Lifesci Capital - MarketBeat
Palvella Therapeutics announces topline results from Phase 2 TOIVA trial - MSN
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst - The Globe and Mail
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 6.6% Following Analyst Upgrade - Defense World
Canaccord Genuity Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Palvella Therapeutics (NASDAQ:PVLA) Trading Up 6.6% on Analyst Upgrade - MarketBeat
Palvella Therapeutics stock price target raised by Chardan to $174 on cVM trial - Investing.com Canada
Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer - Yahoo Finance
Analyst Raises Price Target for PVLA with Maintained Buy Rating - GuruFocus
TD Cowen Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $133.00 - MarketBeat
Adagene, Palvella up after FDA Fast Track tags (ADAG:NASDAQ) - Seeking Alpha
Palvella Therapeutics stock price target raised to $193 at Raymond James - Investing.com Canada
Palvella Therapeutics Says US FDA Grants Potential Lesion Therapy Fast-Track Designation - marketscreener.com
Chardan Boosts Price Target on Palvella Therapeutics to $174 From $110, Keeps Buy Rating - marketscreener.com
Accenture To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday - Sahm
FDA grants fast track designation for Palvella’s skin disease therapy By Investing.com - Investing.com Canada
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas - The Manila Times
Palvella Therapeutics Granted FDA Fast Track Designation - GlobeNewswire
Palvella Therapeutics stock price target raised to $133 from $97 at TD Cowen - Investing.com Canada
Palvella Therapeutics stock hits 52-week high at 110.34 USD - Investing.com India
Palvella Therapeutics stock price target raised to $192 at BTIG on positive trial data - Investing.com Canada
2.52%
0.07%
大文字化:
|
ボリューム (24 時間):